Preimplantation Genetic Testing Market Size - Share Outlook, Growth Analysis Report and Forecast Trends 2026-2030

Preimplantation genetic testing involves screening embryos created through IVF for genetic disorders prior to uterine transfer. The market includes three primary testing categories: PGT-A (aneuploidy), PGT-M (monogenic diseases), and PGT-SR (structural rearrangements). Current market valuation sits around $0.85 billion globally, with varying estimates across research firms reflecting methodological differences in scope and geographic coverage.

• •2025 market value ranges from $690 million to $929 million across leading research estimates
• •Testing services primarily serve fertility clinics, hospitals, and diagnostic laboratories
• •Technological advancements in next-generation sequencing are improving test accuracy and adoption rates

The rising global prevalence of infertility, increasing maternal age at first pregnancy, and greater awareness of genetic screening options are fueling market expansion. Improved accuracy of genetic testing technologies and declining costs per test are making PGT more accessible to broader patient populations.

• •Rising IVF procedure rates globally, particularly in emerging markets with improving healthcare infrastructure
• •Growing demand for preventing hereditary disease transmission, especially among couples with known genetic risks
• •Technological improvements in whole genome amplification and next-generation sequencing reducing false-positive rates

The market is segmented by test type (PGT-A, PGT-M, PGT-SR), technology platform (PCR, FISH, NGS), and end-user setting (hospitals, clinics, diagnostic labs). North America dominates due to advanced healthcare infrastructure and high IVF penetration, while Asia-Pacific shows the fastest growth trajectory driven by increasing fertility treatment adoption in China, India, and Southeast Asia.

• •North America represents the largest regional share, supported by favorable reimbursement policies and high awareness
• •Europe maintains significant market presence with regulatory frameworks supporting advanced genetic testing
• •Asia-Pacific emerges as the fastest-growing region, with expanding IVF clinic networks and rising disposable incomes

What are the recent trends and outlook?

The market is moving toward more comprehensive whole-genome embryo screening and non-invasive testing methods using spent embryo culture media. Integration of artificial intelligence for embryo selection based on genetic and morphological data represents an emerging opportunity. Long-term growth projections through 2030-2036 remain positive, with most estimates forecasting the market to exceed $1 billion within the next five years.

• •Non-invasive PGT using embryo culture media eliminates the need for embryo biopsy, potentially improving implantation rates
• •AI and machine learning applications are being developed to enhance genetic data interpretation and embryo selection accuracy
• •Expanding regulatory approvals for comprehensive chromosome screening across more geographic markets